Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

Core Insights - Altamira Medica Ltd. announced that its Bentrio® nasal spray has been independently tested and found free of over 230 prohibited substances listed by the World Anti-Doping Agency (WADA), confirming its suitability for athletes [1][3] - The nasal spray is designed to protect against airborne allergens and particles while complying with anti-doping regulations, addressing the challenges athletes face in managing allergic rhinitis [2][3] Company Overview - Altamira Therapeutics Ltd. is focused on developing peptide-based nanoparticle technologies for RNA delivery, with two flagship siRNA programs in preclinical development targeting KRAS-driven cancer and rheumatoid arthritis [5][6] - The company holds a 49% stake in Altamira Medica AG, which commercializes Bentrio®, an over-the-counter nasal spray for allergic rhinitis [6] Product Details - Bentrio® is a drug-free and preservative-free nasal spray that forms a protective gel layer on the nasal mucosa, preventing airborne particles from contacting cells and aiding in their discharge [4] - Clinical trials, including the NASAR study with 100 participants, demonstrated Bentrio's efficacy in reducing allergy symptoms and improving quality of life, with statistically significant results [4]